Loading…
Traws Pharma, Inc. is projected to decline to $0.4061 by 2027, a -14% move from its current price of $0.4716. TRAW is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.4465 | $0.4713 | $0.4975 | -0.06% |
| Aug 6 | $0.4364 | $0.471 | $0.5085 | -0.12% |
| Aug 7 | $0.4287 | $0.4708 | $0.517 | -0.18% |
| Aug 8 | $0.4223 | $0.4705 | $0.5242 | -0.24% |
| Aug 9 | $0.4167 | $0.4702 | $0.5306 | -0.30% |
| Aug 10 | $0.4116 | $0.4699 | $0.5364 | -0.36% |
| Aug 11 | $0.4071 | $0.4696 | $0.5418 | -0.42% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.4071 | $0.4696 | $0.5418 | -0.42% |
| Week 2 | $0.382 | $0.4677 | $0.5725 | -0.83% |
| Week 3 | $0.3635 | $0.4657 | $0.5966 | -1.24% |
| Week 4 | $0.3484 | $0.4638 | $0.6174 | -1.66% |
| Week 5 | $0.3354 | $0.4619 | $0.6359 | -2.07% |
| Week 6 | $0.324 | $0.4599 | $0.6529 | -2.47% |
| Week 7 | $0.3137 | $0.458 | $0.6687 | -2.88% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Traws Pharma, Inc. is a healthcare company in the biotechnology sector that develops small synthetic molecules for respiratory viral diseases and cancer. The description identifies it as a clinical-stage biopharmaceutical company pursuing investigational therapies for influenza and COVID-19, including TRX01 (Ratutrelvir) and Tivoxavir marboxil, as well as narazaciclib and rigosertib.
It is headquartered in Newtown, Pennsylvania and was incorporated in 1998; the company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024.
It maintains license agreements with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., Knight Therapeutics Inc., Specialised Therapeutics Asia Pte. Ltd., and Temple University. The description places it in the Healthcare category.
Traws Pharma operates as a clinical-stage entity focused on therapies for respiratory viral diseases and cancer, with multiple investigational programs and collaborative licenses that support its development efforts. The narrative highlights its historical name change, its incorporation date, and its Newtown, PA headquarters, framing it within the healthcare biotechnology landscape.
Traws Pharma, Inc. (TRAW) is trading at $0.4411 with a market capitalization of $6.72M and a market rank of 4920. This places the stock in the micro-cap to small-cap tier within the healthcare sector.
The near-term technical picture shows a neutral stance, with key support near the current price and resistance higher on the chart. The stock exhibits high volatility, consistent with the tiny market cap and speculative biotech focus.
Overall, the price outlook derived from the forecast data suggests modest upside through 2030, followed by more notable upside into the 2040s and beyond, but with notable volatility and several years of negative returns in the interim. The combination of a low price level, conservative near-term forecast, and later bullish legs underscores a high-risk, high-reward profile typical of clinical-stage biopharma stocks.
A major floor 69.6% below — a decisive break under it would weaken the trend.
The nearest floor, 6.7% below — buyers have tended to step in here.
The nearest ceiling, 88.7% above — a clean break opens room to run.
A major ceiling 362.3% above — clearing it would confirm fresh momentum.
Key TRAW support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TRAW market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.48 | Sell | $0.4757 | Sell |
| MA 10 | $0.517 | Sell | $0.5193 | Sell |
| MA 20 | $0.6055 | Sell | $0.6116 | Sell |
| MA 50 | $0.9442 | Sell | $0.8817 | Sell |
| MA 100 | $1.31 | Sell | $1.18 | Sell |
| MA 200 | $1.67 | Sell | $1.64 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 26.66 | Buy |
| Stoch RSI (14) | 15.58 | Buy |
| CCI (20) | -115.96 | Sell |
| Williams %R (14) | -96.15 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -30.77 | Sell |
| Bollinger %B (20,2) | 0.12 | Neutral |
| Stochastic %K (14) | 3.85 | Buy |
| TRIX (15) | -2.34 | Sell |
| Awesome (5,34) | -0.23 | Sell |
| Ultimate (7,14,28) | 22.96 | Buy |
| Momentum (10) | -0.22 | Sell |
| Aroon Osc (25) | -84.00 | Sell |
| Hull MA (9) | 0.45 | Buy |
| ADX (14) | 38.86 | Sell |
| ATR (14) | 0.04 | Info |
The 30-day technical picture is Neutral overall. RSI14 is 30, indicating modest near-term downside pressure, while the 50-day simple moving average sits at $0.967 and the 200-day average at $1.68, suggesting the current price sits below both averages. Price action remains supported around $0.44, with resistance at $0.89 on the chart.
The 30-day range spans from $0.3061 to $0.6356, illustrating a relatively wide trading band for a low-priced biotech. The stock’s 30-day backdrop reflects a balance between selling pressure and occasional buying interest, consistent with a Neutral stance and elevated volatility.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.44 | $0.4716 | $0.5976 | 0% | Neutral | |
| $0.2959 | $0.4061 | $0.6022 | -14% | Neutral | |
| $0.253 | $0.3693 | $0.5844 | -22% | Bearish | |
| $0.2616 | $0.4024 | $0.6689 | -15% | Neutral | |
| $0.3023 | $0.4876 | $0.8443 | +3% | Neutral | |
| $0.3121 | $0.5262 | $0.9433 | +12% | Neutral | |
| $0.3378 | $0.5942 | $1.10 | +26% | Bullish | |
| $0.2979 | $0.5457 | $1.04 | +16% | Neutral | |
| $0.2418 | $0.4608 | $0.8982 | -2% | Neutral | |
| $0.2501 | $0.4954 | $0.9881 | +5% | Neutral | |
| $0.3179 | $0.7064 | $1.55 | +50% | Bullish | |
| $0.5956 | $1.32 | $3.04 | +181% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.44 | $0.4716 | $0.6079 | +0.00% |
| September 2026 | $0.3919 | $0.4764 | $0.6042 | +1.02% |
| October 2026 | $0.3624 | $0.4466 | $0.578 | -6.25% |
| November 2026 | $0.3618 | $0.451 | $0.5931 | +0.98% |
| December 2026 | $0.3555 | $0.4479 | $0.5976 | -0.69% |
Click any year to see its month-by-month TRAW forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, TRAW is projected to trade between $0.44 and $0.5976, averaging $0.4716 — a potential gain of 0% from today's $0.4716. A consolidation phase looks the most probable path here.
Traws Pharma, Inc.'s 2027 outlook centres on $0.4061, within a $0.2959 to $0.6022 range. That is -14% versus the projected 2026 average. That marks a -14% change versus current levels. Price action looks broadly range-bound.
By 2028, TRAW could reach as high as $0.5844, with a base case around $0.3693 and support toward $0.253 — roughly -22% from $0.4716. Expect choppier, lower action through this leg of the cycle.
Expect TRAW to range from $0.2616 to $0.6689 through 2029. The $0.4024 average target implies a -15% move from current prices. That is up +9% on the projected 2028 average. Price action looks broadly range-bound.
The TRAW price prediction for 2030 points to an average of $0.4876 (low $0.3023, high $0.8443) — a potential gain of +3% on today's $0.4716. A consolidation phase looks the most probable path here.
In 2031, TRAW is projected to trade between $0.3121 and $0.9433, averaging $0.5262 — a potential gain of +12% from today's $0.4716. That is up +8% on the projected 2030 average. Price action looks broadly range-bound.
Traws Pharma, Inc.'s 2032 outlook centres on $0.5942, within a $0.3378 to $1.10 range. That is up +13% on the projected 2031 average. That marks a +26% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, TRAW could reach as high as $1.04, with a base case around $0.5457 and support toward $0.2979 — roughly +16% from $0.4716. Price action looks broadly range-bound.
Expect TRAW to range from $0.2418 to $0.8982 through 2034. The $0.4608 average target implies a -2% move from current prices. That is -16% versus the projected 2033 average. A consolidation phase looks the most probable path here.
The TRAW price prediction for 2035 points to an average of $0.4954 (low $0.2501, high $0.9881) — a potential gain of +5% on today's $0.4716. Price action looks broadly range-bound.
In 2040, TRAW is projected to trade between $0.3179 and $1.55, averaging $0.7064 — a potential gain of +50% from today's $0.4716. That is up +43% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Traws Pharma, Inc.'s 2050 outlook centres on $1.32, within a $0.5956 to $3.04 range. That is up +87% on the projected 2040 average. That marks a +181% change versus current levels. Momentum favours further upside here.
Investing $1,000 in TRAW today (≈ 2,120.441052 TRAW) could be worth
$2,806.58
+$1,806.58 (+181%) by 2050 · US Dollar
Based on the average projected TRAW price of $1.32 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TRAWwould be worth at today's price.
$1,000 invested in TRAW on Jul 31, 2025 (≈ 649.350665 TRAW) would be worth
$306.23
-$693.77 (-69.4%) today · 0.31× · US Dollar
Based on a TRAW entry price of $1.54 vs. today's $0.4716.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.49 | $962.45 | -3.8% |
| 1 month ago | $0.81 | $582.22 | -41.8% |
| 3 months ago | $1.49 | $316.51 | -68.3% |
| 6 months ago | $2.04 | $231.18 | -76.9% |
| 1 year ago | $1.54 | $306.23 | -69.4% |
| All time (5.0y) ago | $128 | $3.68 | -99.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TRAW forecast.
Our base-case forecast reaches $0.94 around 2050.
Implied market cap at $0.94: $14.31M
The multi-year forecast shows a path of mixed momentum through the mid-term, with the potential for meaningful upside later in the horizon. By 2030, the average forecast price is $0.4537 with a min of $0.2811 and a max of $0.7858, and an ROI of 2.9% in a Neutral sentiment environment.
By 2040 the forecast projects stronger upside, with an average of $0.6648 and a max of $1.46, yielding a 50.7% ROI in a Bullish-leaning context. By 2050 the average is $1.23 and the max $2.83, with an ROI of 178.6% and a Bullish sentiment, signaling substantial long-run upside in the outer horizon.
Bearish periods appear in the nearer years, including 2027 (avg $0.3754, ROI -14.9%), 2028 (avg $0.3483, ROI -21%), and 2029 (avg $0.3716, ROI -15.8%), underscoring the uncertainty and risk inherent in the path from a micro-cap biotech stock. Overall, the forecast envisions gradual appreciation into the 2030s and beyond, tempered by volatility and the episodic risk of downside.
Tap a question to reveal the answer.
The average forecast price for 2030 is $0.4537, with a min of $0.2811 and a max of $0.7858, and a ROI of 2.9%; sentiment NEUTRAL.
Forecasts show mixed signals: 2026 avg $0.4411 with 0% ROI; 2030 avg $0.4537 (2.9% ROI); 2040 avg $0.6648 (50.7% ROI); 2050 avg $1.23 (178.6% ROI). Some intermediate years are bearish (e.g., 2027 ROI -14.9%, 2028 ROI -21%, 2029 ROI -15.8%). This suggests limited near-term upside with potential longer-term gains, but no guarantees.
Yes. The forecast shows a max of $1.03 in 2032 and a max of $1.46 in 2040, with a long-run max of $2.83 by 2050.
Current price is $0.4411 and the market capitalization is $6.72M.
Near-term, the sentiment is NEUTRAL with RSI14 at 30. The stock trades relative to SMA50 of $0.967 and SMA200 of $1.68, with support at $0.44 and resistance at $0.89. The 30-day range is $0.3061-$0.6356 and volatility is high (annualized volatility 100%).
Traws Pharma, Inc. Community Discussion
0Share your Traws Pharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.